NEW YORK (GenomeWeb) – Liquid biopsy developer Biocept announced a $15 million public offering today of up to about 33.3 million shares of its common stock with warrants to purchase up to an aggregate of approximately 33.3 million more shares at a combined price of $0.45.

The warrants will have a per share exercise price of $0.50, are exercisable immediately, and will expire five years from the date of issuance, the company said. Dawson James Securities and WestPark Capital are acting as placement agents in connection with the offering, and Dawson James served as sole bookrunner.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.